摘要
OBJECTIVE: To investigate the expression of cluster of differentiation 44 variant 6 (CD(44V6)) and proliferating cell nuclear antigen (PCNA) in ocular squamous cell carcinomas. METHODS: Streptavidin-biotin complex (SABC) immunohistochemistry was used to explore the expression of CD(44V6) and PCNA in 35 cases of ocular squamous cell carcinomas, 20 cases of papillomas, and 11 cases of normal eyelid tissue. RESULTS: The CD(44V6) positive rate was 62.9% (22/35) in ocular squamous cell carcinomas, 15.0% (3/20) in papillomas, but not detectable in the 11 cases of normal eyelid tissue. The positive expression rates of CD(44V6) in ocular squamous cell carcinomas were significantly higher than in benign tumors (chi(2) = 11.57, P
目的探讨眼部鳞状细胞癌中细胞黏附分子变异体6(cluster of differentiation 44 variant 6 ,CD44V6)表达及与增殖细胞核抗原(proliferating cell nuclear antigen,PCNA )的关系.方法应用链霉亲和素-生物素-过氧化物酶复合物免疫组化法检测35例眼部鳞状细胞癌、20例乳头状瘤和11例正常眼睑皮肤组织标本CD44V6蛋白表达.结果 CD44V6蛋白在眼部鳞状细胞癌(squamous cell carcinoma,SCC)的阳性表达率为62 .9%(22/35),而在乳头状瘤的阳性表达率为15.0%(3/20),在11例正常眼睑皮肤组织均无CD44V6蛋白的阳性表达;恶性组CD44V6蛋白的阳性表达率明显高于良性组 (χ2=11.57,P<0.01)和正常组(P=0.001),8例淋巴转移的CD44V6蛋白的阳性表达率明显高于无转移者(P=0.049);CD44V6蛋白阳性表达者其PCNA 指数明显高于阴性表达者组,差异有统计学意义(t=20.21,P<0.01).结论 CD44V6分子可能与眼部鳞状细胞癌的恶性表型、浸润及转移有关,CD44V6蛋白的表达与PCNA蛋白表达具有正相关性,二者的同时检测对评估患者的预后可能有临床参考价值.
